Vpriv® (velaglucerase alfa)

Vpriv (velaglucerase alfa) is covered for Type 1 Gaucher disease (FDA‑approved) and for Type 3 only as an off‑label compendial treatment for non‑neurologic manifestations (impaired growth, hematologic or visceral symptoms) and is excluded for neurological manifestations. Coverage requires age ≥4 years, biochemical (reduced β‑glucocerebrosidase) or biallelic GBA genetic confirmation, prescription by or consultation with a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, adherence to dosing limits (Type 1: 60 U/kg IV q2w; Type 3: ≤120 U/kg IV q2w), documentation of non‑neurologic indication, and authorization is limited to 1 year.

"Type 1 Gaucher disease (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.